Edgardo S. Santos

May 22, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Adverse Events Associated With TKIs in HER2-Mutated NSCLCD. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

May 15, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities PersistDr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate CancerDr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCCDarolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 8, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities PersistDr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate CancerDr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCCDarolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 1, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial CancerAs Orthopedic Oncology Evolves, Caring for the Clinician Must Be a PriorityBelumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHDProphylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

May 1, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLCExperts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.